

# Immunohistochemical and Tissue Array Study for Comparison of the Expression of Tumor Suppressor Genes and with Intercellular Adhesive Molecules in Colorectal Adenocarcinoma and Nontumoral Colon

Niloofar Sodeifi, Ph.D.<sup>1</sup>, Masood Sotoudeh, Ph.D.<sup>1</sup>, Saeed Shafieyan<sup>2‡</sup>

1. Pathology Department, Dr. Shariati Hospital, Tehran University  
2. Dermatology Department, Firouzabadi Hospital, Iran Medical Science University

<sup>‡</sup>Corresponding Address: P.O. Box: 1411713135, Pathology Department, Dr. Shariati Hospital, Tehran University, Tehran, Iran  
Email: sotoudeh@ams.ac.ir

**Received: 2006/May/28, Accepted: 30/Oct/2006**

**Introduction:** Colorectal Carcinoma is a main health problem in many countries and the third common cancer in Iran. This malignancy at present is the most curable carcinoma of gastrointestinal tract. Variation in the expression of the proteins produced by P<sub>53</sub>, P<sub>21</sub>, P<sub>16</sub>, E-cadherin, and  $\beta$ -catenin genes have been noted in this malignancy and may be important in the prognosis and therapeutic response rate. The aim of this study was to compare the frequency and pattern of expression of these proteins in tumoral and nontumoral colonic mucosa. The correlation with prognostic factors including tumor stage, grade, and vascular and perineural invasion was also determined.

**Material and Methods:** The paraffin blocks from tumoral and nontumoral parts of the colon obtained from 58 patients with colorectal adenocarcinoma were studied along with 50 colectomic cases in individuals without malignancy. Cylindrical tissue fragments were obtained from appropriate parts of donor blocks by using a 2.5 mm punch biopsy instrument. Each 30 samples were manually arrayed in one tissue array block. Expression of above genes was investigated after sectioning the blocks and immunohistochemical staining of slides.

**Results:** The expression of P<sub>53</sub> in tumor cells was significantly more common than in colonic nontumor cells and colon of individuals without tumor ( $p < 0.001$ ); expression of this protein in tumoral tissues was directly related to vascular invasion ( $p = 0.017$ ). The expression frequency of P<sub>21</sub> and P<sub>16</sub> in tumor cells was less than nontumoral tissues of patients with cancer and patients without cancer ( $p < 0.001$ ). These two gene products showed no correlation with prognostic factors. The expression frequency of membranous E-cadherin and  $\beta$ -catenin in tumor cells was not different from controls, while the membranous expression of E-cadherin was inversely related to cell differentiation ( $p = 0.023$ ) and vascular invasion ( $p = 0.025$ ). In addition, the membranous expression of  $\beta$ -catenin was inversely related to vascular invasion ( $p = 0.049$ ). Cytoplasmic and nuclear expression of  $\beta$ -catenin in tumor cells were significantly higher than their expression in the controls ( $p < 0.001$ ). Cytoplasmic expression of this marker was inversely related to disease stage ( $p = 0.013$ ), while its nuclear expression was inversely related to cell differentiation ( $p = 0.012$ ).

**Conclusion:** According to our data, it seems that we are able to predict aggressive capacity of the colorectal tumor by determining the frequency and pattern of expression of P<sub>53</sub>, E-cadherin and  $\beta$ -catenin proteins. These studies can be done simply on formalin-fixed small biopsy samples before surgery to provide valuable information for surgeons, gastroenterologists, and oncologists to choose the best therapeutic approach and predict the therapeutic response. Manual tissue array method is believed to be an economical technique for similar research projects.

**Keywords:** Colorectal adenocarcinoma, Immunohistochemistry, Tissue array, P<sub>53</sub>, P<sub>16</sub>, P<sub>21</sub>, E-cadherin, beta catenin

## Introduction

Colorectal carcinoma is a malignant epithelial tumor of large intestine with glandular growth pattern (1). In USA, colorectal carcinoma is the fourth common malignancy after breast, prostate, and lung cancer, and also the most common and curable malignancy of gastrointestinal tract (2). It is the third common cancer in Iran (3). Adenocarcinomas constitute about 98% of all large bowel malignancies (4, 5). The peak of incidence is between 60-79 (mean 62) years old (1, 5, 6). Genetic, environmental, and dietary factors and pelvic irradiation have all been implicated in the appearance of this carcinoma (1). Most cases occur sporadically (5). Molecular carcinogenesis in colorectal adenocarcinoma includes two separate pathways: APC/ beta-catenin pathway (containing mutation of APC tumor suppressor gene, mutation of beta-catenin, k-ras, P<sub>53</sub>, and SMAD4 and telomerase activity) and microsatellite instability pathway or genetic defect in DNA mismatch repair genes. Mutation in E-cadherin, beta-catenin and Von-Hippel-Lindau genes are known findings (1, 3). Wild type P<sub>53</sub> has several roles in cell cycle; it causes cell cycle arrest at the end of G<sub>1</sub> phase via induction of P<sub>21</sub> waf<sub>1</sub>/ Cip<sub>1</sub>, induces transcription of GADD45 involved in DNA repair, and finally induces apoptosis via BAX gene (a Bcl<sub>2</sub> inhibitor) (1, 7). Wild P<sub>53</sub> is not detectable by IHC (because of short half life of about 20 min). Mutant P<sub>53</sub> has lost its ability to suppress cell proliferation, has long half life (6h), and is detectable by IHC in nucleus (1). Tumor cells containing mutant P<sub>53</sub> are resistant to apoptosis induced by radiotherapy and chemotherapy (1). P<sub>21</sub> waf<sub>1</sub>/ Cip<sub>1</sub> is a tumor suppressor gene that its synthesis is induced by P<sub>53</sub> in response to DNA damage, inhibits cyclin D-CDK<sub>4</sub> complex, and causes cell cycle arrest. It also causes cell cycle arrest in G<sub>2</sub> phase independent to P<sub>53</sub> (1, 7). Wild P<sub>21</sub> is detectable by IHC in nucleus (1, 7). P<sub>16</sub> INK 4a is a tumor suppressor gene that inhibits cyclin D-CDK 4 complex and causes cycle arrest (1, 7). Wild P<sub>16</sub> is detectable by IHC in nucleus (1). E-cadherin is a transmembrane glycoprotein that causes intercellular adhesion and is detectable by IHC in cell membrane (1, 7). Beta-catenin which is normally located at cell membrane can activate growth stimulators (C-myc & cyclin

D) by transferring them into cytoplasm and then to nucleus (1, 7).

Tissue array is an array of ten to hundreds of thin cylindrical tissue fragments of various origins in one paraffin block that enables simultaneous analysis of various tissues and controls in the same conditions and saves the time, labor, and costs (8-14).

The aim of this study was to compare the frequency and pattern of expression of these proteins in tumoral and nontumoral colonic mucosa of patients with and without this malignancy. The correlation with prognostic factors including stage, grade, vascular, and perineural invasion was also determined.

## Material and Methods

This research was performed in Dr. Shariati Hospital between 1380-3. Cases were selected from paraffin embedded blocks of tumoral colons of patients with a history of colectomy due to colorectal adenocarcinoma (State 1 or S1). Two different control groups were selected: control 1 (State 2 or S2) including paraffin-embedded blocks of nontumoral colon the patients whose tumors had been selected for S1, and control 2 (State 3 or S3) paraffin-embedded blocks of colectomized patients not affected by adenoma, adenocarcinoma, and IBD (eg. trauma, ischemia, and etc.). Cases with extensive areas of necrosis or hemorrhage were excluded from research (15, 16, 17). The pathology reports were reviewed to find cases and controls. The slides were selected and reviewed. The corresponding paraffin blocks were selected and the areas of interest were marked.

The areas of interest were removed from paraffin blocks by using a disposable 2.5 mm biopsy punch. Selected samples were kept in separate labeled containers. The tissue array moulds, consisting of two pieces of L-shaped metal, were inserted in a microbiology plate to inhibit the paraffin leakage.

The combination of mould and plate were filled with warm liquid paraffin and kept warm during arraying of samples. Thirty core samples including 27 cases and controls and 3 positive controls of IHC markers were arrayed in each block (Figure 1).

The prepared blocks were sliced and the slides were stained by H & E method, and if optimal, by IHC method (Figure 2).




Fig 1




Fig 2

Presumptive positive IHC controls were selected based on previous studies (15-32) and IHC marker catalogues. Thirty cylindrical pieces of suspected tissues were arrayed in one tissue array block that was sliced and stained by IHC method for five markers.

Positively stained samples were chosen, including uterine cervical squamous cell carcinoma (SCC) for P<sub>21</sub>, breast intraductal carcinoma (IDC) for P<sub>53</sub> and P<sub>16</sub>, and normal gastric epithelium or parathyroid adenoma for E-cadherin and beta-catenin.

The IHC results were classified according to staining severity as 0 = negative, 1 = 1+, 2 = 2+, and 3 = 3+, and based on staining extension as 0 = less than 5%, 1 = 5-25%, 2 = 26-50%, 3 = 51-75%, and 4 = 76-100% of cells. Final score was equal to severity × extension, as follows: 0-4 = negative or markedly decreased and 5-12 = positive expression. The results were statistically analyzed by SPSS software and examined by Fisher's exact test or Pearson chi-Square test where needed.

## Results

Fifty eight blocks were found for S1, 58 for S2, and 50 for S3.

Sex distribution in cases and S2 controls was 51.7% male and 48.3% female, while it was 70% male and 30% female in S3 controls. The mean age of cases and S2 controls was 49.55±13.71 (20-75) years, while it was 55.66±17.34 (6-85) years in S3 controls. Tumor type was as follows: NOS 81.9%, mucinous 8.6%, signet ring 3.4%. Location of tumors has been shown in Table 1.

Table 1: Location of tumor.

	Frequency	Percent	Valid Percent	Cumulative Percent
<b>Valid</b>	1.00	14	24.1	24.1
	2.00	6	10.3	34.5
	4.00	2	3.4	37.9
	5.00	14	24.1	62.1
	6.00	9	15.5	77.6
	7.00	10	17.2	94.8
	8.00	1	1.7	96.6
	9.00	2	3.4	100.0
	Total	58	100.0	100.0

a STATE = 1.00

1. Cecum, 2. Ascending colon, 3. Transverse colon, 4. Descending colon, 5. Sigmoid colon, 6. Rectosigmoid colon, 7. Rectum, 8. Anal canal, 9. Not specified

Table 2: Results of comparison between gene expression in various states.

Marker	Difference in state 1 with State 2		Difference in state 1 with State 3		Difference in state 2 with State 3	
	YES P <sub>value</sub> <0.001	Positivity in S <sub>1</sub> >S <sub>2</sub>	YES P <sub>value</sub> <0.001	Positivity in S <sub>1</sub> >S <sub>3</sub>	No	Negativity in S <sub>2</sub> =S <sub>3</sub> = 100 %
P <sub>53</sub>	YES P <sub>value</sub> <0.001	Positivity in S <sub>1</sub> >S <sub>2</sub>	YES P <sub>value</sub> <0.001	Positivity in S <sub>1</sub> >S <sub>3</sub>	No	Negativity in S <sub>2</sub> =S <sub>3</sub> = 100 %
P <sub>21</sub>	YES P <sub>value</sub> <0.001	Negativity in S <sub>1</sub> >S <sub>2</sub>	YES P <sub>value</sub> <0.001	Negativity in S <sub>1</sub> >S <sub>3</sub>	No	
P <sub>16</sub>	YES P <sub>value</sub> <0.001	Negativity in S <sub>1</sub> >S <sub>2</sub>	YES P <sub>value</sub> <0.001	Negativity in S <sub>1</sub> >S <sub>3</sub>	No	
E-cadherin	No		No		No	
β-catenin M	No		No		No	Positivity in S <sub>2</sub> =S <sub>3</sub> = 100 %
β-catenin C	YES P <sub>value</sub> <0.001	Positivity in S <sub>1</sub> >S <sub>2</sub>	YES P <sub>value</sub> <0.001	Positivity in S <sub>1</sub> >S <sub>3</sub>	No	
β-catenin N	YES P <sub>value</sub> <0.001	Positivity in S <sub>1</sub> >S <sub>2</sub>	YES P <sub>value</sub> <0.001	Positivity in S <sub>1</sub> >S <sub>3</sub>	No	

**Table 3: Summary of gene expression in correlation with histologic prognostic factors**

IHC Marker	Stage Fisher's exact test P <sub>value</sub>	Grade Pearson chi square P <sub>value</sub>	Vascular Invasion Fisher's exact test P <sub>value</sub>	Perineural Invasion Fisher's exact test P <sub>value</sub>	Tumor Type Pearson chi square P <sub>value</sub>
P53	1	0.392	0.017	1	0.506
P21	0.783	0.255	0.124	0.700	0.954
P16	0.729	0.220	0.710	1	0.374
E-cadherin	1	0.025	0.023	0.418	0.106
β-catenin M	0.130	0.842	0.049	1	0.044
β-catenin C	0.013	0.038	0.553	1	0.205
β-catenin N	0.284	0.012	0.767	1	0.416

β-catenin M=Membranous

β-catenin C=Cytoplasmic

β-catenin N=Nuclear

Summary of results of gene expression in various states has been shown in Table 2. Correlation between gene expression and prognostic factors is summarized in Table 3.

## Discussion

The P<sub>53</sub> expression in tumor cells was significantly more common than non-tumoral colonic cells of patients with and without colorectal adenocarcinoma ( $p < 0.001$ ). The expression of P<sub>21</sub> & P<sub>16</sub> in tumor cells was significantly less common than non-tumoral colonic cells of patients with and without colorectal adenocarcinoma ( $p < 0.001$ ). The frequency of membranous expression of E-cadherin and beta-catenin were not significantly different in three states. Cytoplasmic and nuclear expression of beta-catenin in tumor cells were significantly more common than non-tumoral colon of subjects with and without colorectal adenocarcinoma ( $p < 0.001$ ). The expression frequency of none of the proteins in non-tumoral colon of patients with colorectal adenocarcinoma was significantly different from unaffected individuals. This finding may be important in distinguishing tumoral from non-tumoral border in tumor resection. The P<sub>53</sub> expression in colorectal adenocarcinoma cells was directly related to vascular invasion ( $p = 0.017$ ).

The frequencies of P<sub>21</sub> & P<sub>16</sub> expression in tumor cells were not related to prognostic factors. The frequency of membranous expression of E-cadherin was inversely related to cell differentiation ( $p = 0.023$ ) and vascular invasion ( $p = 0.025$ ). Frequencies of

Cytoplasmic and nuclear expression of beta-catenin was inversely related to vascular invasion ( $p = 0.049$ ). The frequency of cytoplasmic expression of beta-catenin was inversely related to disease stage ( $p = 0.013$ ).

The frequency of nuclear expression of beta-catenin was inversely related to cell differentiation ( $p = 0.012$ ).

Overall, overexpression of P<sub>53</sub>, underexpression of P<sub>21</sub> & P<sub>16</sub>, and shift of beta-catenin expression from cell membrane to cytoplasm and nucleus in tumor cells were seen more than those in non-tumor colonic cell of patients with and without adenocarcinoma. Expression of membranous E-cadherin and nuclear beta-catenin were directly related to cell differentiation. Vascular invasion was directly associated with P<sub>53</sub> expression and inversely related to membranous expression of E-cadherin and beta-catenin. Perineural invasion was related to none of above markers.

In study of Valassiadou KE *et al.* in 1997 (20) and Goussia AC *et al.* in 2000 (21), P<sub>53</sub> overexpression was inversely related to probability of lymphatic invasion and aggressive potential, as opposed to our study. According to Hirvikoski P *et al.* in 1999 (22) and Acolin A *et al.* in 2005 (23), mutation or overexpression of P<sub>53</sub> was not correlated to prognosis. Diez M *et al.* in 2005 (24) showed that P<sub>53</sub> was the only predictive of high recurrence risk in a subgroup of patients with stage 3 tumors. Mitomi M *et al.* in 2005 (25) showed that down-regulation of P<sub>21</sub> was associated with lymph node and/or liver metastasis. In a study performed by Yasui W *et al.* in 1997 (26), P<sub>21</sub> expression was inversely

associated with invasion to deeper than muscularis propria and tumor progression. Tada T *et al.* in 2003 (27) showed that colorectal cancers with reduced P<sub>16</sub> expression had more aggressive potential of lymphatic infiltration and tumor progression. In our study, reduced expression of P<sub>21</sub> & P<sub>16</sub> was seen in tumoral cells compared to non-tumor cells, while it was not correlated to prognostic factors.

In studies performed by Herter P *et al.* in 1999 (28), Utsunomiya T *et al.* in 2001 (29), and Delektorskaya W *et al.* in 2005 (30), cytoplasmic and nuclear translocation of beta-catenin expression from cell membrane was seen in tumor cells, which was associated with aggressive potential in agreement with our study. In studies performed by Sloncova E *et al.* in 2001 (31) and Jesus EC *et al.* in 2005 (32), expression of E-cadherin was not related to prognostic factors, as opposed to our study which showed inverse relationship between frequency of membranous expression of E-cadherin, and cell differentiation (p=0.023) and vascular invasion (p=0.025).

Colorectal adenocarcinoma is the most common and most curable malignancy of the gastrointestinal tract. Its pathogenesis is influenced by environmental and genetic factors. Genetic factors include proteins that regulate cell replication cycle including P<sub>53</sub>, P<sub>21</sub>, and P<sub>16</sub> tumor suppressor genes, an adhesive molecule called E-cadherin, and beta-catenin which regulates cell cycle and mediates beta-catenin action. Expression of these proteins has been studied in multiple separate studies, which have shown correlation with prognosis and responsiveness to the therapeutic methods in patients with colorectal adenocarcinoma. In this study, we tried to solve the technical problems of tissue array and immunohistochemical staining methods to compare the expression of described proteins in tumor cells of colorectal adenocarcinoma with colonic non-tumor cells of patients with and without adenocarcinoma.

Tissue array method saves morphologic characteristics of tissue samples and saves in time, labor, and cost.

In this study, increased expression of P<sub>53</sub>, decreased expression of P<sub>21</sub> and P<sub>16</sub>, and shift of beta-catenin expression from cell membrane to cytoplasm and nucleus were seen in colorectal adenocarcinoma cells (but not in adjacent colonic cells) as compared to the colon of unaffected people. Cytoplasmic expression of beta-catenin was directly associated with disease stage. In addition, membranous expression of E-cadherin inversely related to tumor grade, while nuclear expression of beta-catenin

was directly related to it. Vascular invasion was accompanied by increased expression of P<sub>53</sub>, and decreased membranous expression of E-cadherin and beta-catenin. Perineural invasion was not associated with any change in expression of above proteins.

## Conclusion

The aggressive capacity of colorectal adenocarcinoma can be predicted by determining the frequency and pattern of expression of P<sub>53</sub>, P<sub>21</sub>, P<sub>16</sub>, E-cadherin, and beta-catenin proteins. These studies can be done simply on formalin-fixed small biopsy samples, probably providing reliable information for surgeons, gastroenterologists, and oncologists to select the best therapeutic approach and predict therapeutic response rate. Expression of these markers may be helpful in marking of tumoral and non-tumoral areas of tumoral colons. The tissue array method enables multiple cores to be analyzed simultaneously and in the same conditions and so significantly saving the time, labor, and costs.

The manual method of tissue array is an economical method compared to automated tissue array and can be used as a technique for future diagnostic applications and researches.

## References

1. Kumar V, Abbas AK, Fausto N, Neoplasia Chen L, James M, Grawford. The gastrointestinal tract. In: Kumar V, Abbas AK, Fausto N. Robbins and Cotran Pathologic basis of disease. 7<sup>th</sup> ed. Philadelphia: Elsevier Saunders; 2005; 269-342, 859-868
2. Rosai J. Gastrointestinal tract. In: Rosai J. Rosai and Ackerman's Surgical pathology. 9<sup>th</sup> ed. Edinburg: Mosby; 2004; 799-821
3. Sadjadi A, Malekzadeh R, Derakhshan MH, Sepehr A, Nouraie M, Sotoudeh M, Yazdanbod A, Shokoohi B, Mashayekhi A, Arshi S, Majidpour A, Babaei M, Mosavi A, Mohagheghi MA, Alimohammadian M. Cancer occurrence in Ardabil: Result of a population-based cancer registry from Iran. *Int. J. Cancer.* 2003; 107: 113-118
4. Skibber JM, Minsky BD, Hoff PM. Cancer of the colon. In: Devita JR, Hellman S, Rosenbreg SA. *Cancer principles & practice of oncology.* 6th ed. Philadelphia: Lippincott Williams & Wilking. 2001; 1217-1219
5. Haskell CM. Colorectal cancer Natural history, diagnosis and staging. In: Haskell CM. *Cancer Treatment.* 5th ed. Philadelphia: W.B. Saunders Company; 703-705
6. Bresalier RS. Malignant neoplasms of the large intestine. In: Feldman M, Friedman LS, Sleisenger MH. *Sleisenger & Fordteran's Gastrointestinal and liver disease Pathophysiology/ Diagnosis/ Management.* 7th ed. Philadelphia: Saunders; 2002; 2215-2217, 2227

7. Sherbet GV, Lakshmi MS. The Genetics of Cancer, Genes Associated With Cancer Invasion, Metastasis and Cell Proliferation. 1st ed. San Diego: Academic Press; 1997; 29-31, 66-67, 77, 103-106, 174, 204-205
8. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. *Nat Med.* 1998; 4(7): 844-887
9. Packeisen J, Korsching E, Herbst H, Boecker W, Buerger H. Desmestified... Tissue microarray technology. *Molecular pathology.* 2003; 56: 198-204
10. Hoos A, Urist MJ, Stojadinovic A, Mastorides S, Dudas ME, Leung DH, Kuo D, Brennan MF, Lewis JJ, Cordon-Cardo C. Validation of microarrays for immunohistochemical profiling of cancer specimen using the examples of human fibroblastic tumor. *Am. J. Pathol.* 2001; 158: 1245-1251
11. Wang L, Deavers MT, Deavers MT, Malpica A, Silva EG, Liu J. Tissue microarray: a simple and cost effective method for high-throughput studies. *Appl Immunohistochem Mol Morphol.* 2003; 174-176
12. Pan CC, Chen PC, Chiang H. An easy method for manual construction of high-density tissue arrays. *Appl Immunohistochem Molecul Morphol.* 2004; 12(4): 370-372
13. Hidalgo A, Pina P, Guerrero G, Lazos M, Salcedo M. A simple method for construction of small format tissue arrays. *J Clin Pathol.* 2003; 56:144-146
14. Wang SL, Yang CH, Chen HH, Chai CY, A Simple and economic method for the manual construction of well-aligned tissue arrays. *Pathol Res Pranc.* 2006; 22(Epub ahead of print)
15. Jourdan F, Sebbagh N, Comperat E, Mourra N, Flahault A, Olschwang S, Duval A, Hamelin R, Flejou JF. Tissue microarray technology: validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression. *Virchow Arch.* 2003; 443 (2): 115-121
16. Diez M, Medrano M, Muguerza JM, Ramos P, Hernandez P, Villeta R, Martin A, Nogueras F, Ruiz A, Granell J. Influence of tumor localization on the prognostic value of p53 protein in colorectal adenocarcinomas. *Anticancer Res.* 2000; Sep-Oct20 (5c): 3907-3912
17. Shu M, Liu S, Yu P. Expression and significance of p53, C-erb B2, CEA proteins in colorectal adenoma and carcinoma. *Hunan Yi ke Da Xue Bao.* 1998; 23(2) 129-132
18. Mac kay JA, Douglas JJ, Ross VG, Curran S, Murray GI, Cassidy J, Mcload HL. Cyclin D1, protein expression and gene polymorphism in colorectal cancer. *Int J Cancer.* 2000; Oct1; 88(1): 77-81
19. Liang Z, Liu F, Luo Y. Detection of the expression of p21, p53, p185 proteins and the mutation of ras, p53 genes in colorectal adenoma and carcinoma. *Zhonghua Bing Li Xue Za Zhi.* 1995; 24 (6): 352-355
20. Valassiadou KE, Stefanaki K, Tzardi M, Datseris G, Geosgioulas V, Melissas J, Tsiftsis DD, Delides G, Kanavaros P. Immunohistochemical expression of p53, Bcl2, mdm2 and Waf1/p21 proteins in colorectal adenocarcinomas. *Anticancer Res.* 1997; 17 (4A): 2571-2576
21. Goussia AC, Ioachim E, Agnantis NJ, Mahera M, Tsanos EV. Bcl2 expression in colorectal tumours Correlation with p53, mdm2, Rb, proteins and proliferation indices. *Histol Histopathol.* 2000; 15(3): 667-672
22. Hirvikoski P, Auvinen A, Servomma K, Kiuru A, Rytomaa T, Makkonen K, Kosma VM. K-ras and p53 mutations and overexpression as prognostic factors in female rectal carcinoma. *Anticancer Res.* 1999; 19(1B): 685-691
23. Colin A, Smith G, Carey FA, Wolf CR, Steele RJ. The prognostic significance of K-ras, P53 and APC mutations in Colorectal carcinoma. *Gut* 2005 ; 54(9): 1283-1386
24. Diez M, Pollan M, Ramos P, Villeta R, Ratia T, Hernandez P, Lozano O, Nogueras F, Granell J. Variation in the prognostic value of P53 protein in relation to tumoral stage in patients with colorectal adenocarcinoma. *Cir Esp.* 2005; 77(4): 213-220
25. Mitomi H, Mori A, Kanazawa H, Nishiyama Y, Ihara A, Otani Y, Sada M, Kobayashi K, Igarashi M. Venous invasion and down-regulation of P21 (WAF1/CIP) are associated with metastasis in colorectal carcinomas. *Heptogastro emt.* 2005; 52(65): 1421-1426
26. Yasui W, Akama Y, Yokozaki H, Semba S, Kudo Y, Shimamoto F, Tahara E. Expression of p21 Waf1/Cip1 in colorectal adenomas and adenocarcinomas and its correlation with p53 protein expression. *pathol Int.* 1997 Jul; 47(7): 470-477
27. Tada T, Watanabe T, Kazana S, Kanazawa T, Hata K, Komuro Y, Nagawa H. Reduced p16 expression correlates with lymphatic invasion in colorectal cancer. *Hepatogastroenterology.* 2003; 50(54): 1756-1760
28. Herter P, Kuhn C, Muller KM, Wittinghofer A, Muller O. Intracellular distribution of beta-catenin in colorectal adenomas, carcinomas and peutz-jeghers polyps. *J Cancer Res Clin Oncol.* 1997; 125(5): 297-304
29. Utsunomiya T, Doki Y, Takemoto H, Shiozaki H, Yano M, Sekimoto M, Tamura S, Yasuda T, Fujiwara Y, Monden M. Correlation of beta-catenin and Cyclin D1 expression in colon cancers. *Oncology.* 2001; 61(3): 226-233
30. Declektorskava VV, Pervoshchikov AG, Golovkov DA, Kushlinskii NE. Expression of E-cadherin, beta-catenin, and CD-44v6 cell adhesion molecules in primary tumors and metastases of colorectal adenocarcinoma. *Bull Exp Biol Med.* 2005; 139(6): 706-710
31. Sloncová E, Fric P, Kucerová D, Lojda Z, Tuňáková Z, Sovová V. Changes of E-cadherin and beta-catenin in human and mouse intestinal tumours. *Histochem J.* 2001; 33(1): 13-17
32. Jesus EC, Matos D, Artigiani R, Watzberg AF, Goldenberg A, Saad SS. Assessment of staging, prognosis and mortality of colorectal cancer by tumor markers: receptor erbB-2 and cadherins. *Acta Cir Bras.* 2005; 20(6): 422-427